9-Sep-2026
No headlines found.
Globe Newswire (Tue, 8-Sep 5:42 PM ET)
Business Wire (Thu, 20-Aug 11:00 AM ET)
Business Wire (Thu, 20-Aug 9:00 AM ET)
Business Wire (Wed, 19-Aug 6:17 PM ET)
Business Wire (Thu, 13-Aug 8:00 PM ET)
Globe Newswire (Wed, 5-Aug 8:00 PM ET)
Business Wire (Tue, 4-Aug 1:39 AM ET)
Dr. Reddy's Laboratories (RDY) Securities Investigation Notice - Levi & Korsinsky
PRNewswire (Fri, 31-Jul 10:07 AM ET)
Globe Newswire (Wed, 29-Jul 10:07 AM ET)
Business Wire (Tue, 28-Jul 10:07 AM ET)
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
DR Reddy's Laboratories trades on the NYSE stock market under the symbol RDY.
As of September 9, 2026, RDY stock price was flat at $11.88 with 2,789,990 million shares trading.
RDY has a beta of -0.16, meaning it tends to be less sensitive to market movements. RDY has a correlation of 0.01 to the broad based SPY ETF.
RDY has a market cap of $9.90 billion. This is considered a Mid Cap stock.
Last quarter DR Reddy's Laboratories reported $853 million in Revenue and $.06 earnings per share. This fell short of revenue expectation by $-73 million and missed earnings estimates by -$.11.
In the last 3 years, RDY traded as high as $84.46 and as low as $11.36.
The top ETF exchange traded funds that RDY belongs to (by Net Assets): EMOP, VWO, AVEM, SPEM, VXUS.
RDY has underperformed the market in the last year with a price return of -15.5% while the SPY ETF gained +18.7%. RDY has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -8.9% and -3.7%, respectively, while the SPY returned +3.4% and -0.5%, respectively.
RDY support price is $11.74 and resistance is $12.02 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RDY shares will trade within this expected range on the day.
